The randomized phase III Iressa Pan-ASia Study ( IPASS ; ClinicalTrials.gov identifier NCT00322452 ) of first-line gefitinib versus chemotherapy analyzed samples meeting preplanned specifications ( n = 437 evaluable for EGFR mutation ; n = 261 mutation-positive ) .